HIIFS
HRTX icon

Harel Insurance Investments & Financial Services’s Heron Therapeutics HRTX Stock Holding History

Harel Insurance Investments & Financial Services’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,000
Closed -$681K – 796
2020
Q4 		$681K Buy
+10,000
New +$174K 0.02% 320

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Harel Insurance Investments & Financial Services's HRTX Position: Q1 2021 in Review

Harel Insurance Investments & Financial Services sold out of Heron Therapeutics (HRTX) in Q1 2021, closing a stake of 10,000 shares — an estimated $681K sold.

Harel Insurance Investments & Financial Services first reported a position in HRTX in Q4 2020 and held it in 1 quarter. The position peaked at $681K in Q4 2020. 193 funds tracked by Wall St. Rank hold HRTX as of Q1 2021.

  • Harel Insurance Investments & Financial Services reported no remaining Heron Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Harel Insurance Investments & Financial Services sold 10,000 Heron Therapeutics shares in Q1 2021, an estimated $681K.
  • Harel Insurance Investments & Financial Services first reported a position in Heron Therapeutics in Q4 2020 and held it in 1 quarter.
  • Harel Insurance Investments & Financial Services's Heron Therapeutics position peaked at $681K in Q4 2020.
  • 193 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2021.

Based on Harel Insurance Investments & Financial Services's 13F filing for Q1 2021, filed 27 Apr 2021.